TherapeuticsMD (TXMD) Invested Capital (2010 - 2026)

TherapeuticsMD has reported Invested Capital for 17 years, with the latest figure at $27.0 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 0.87% year-over-year to $27.0 million; the trailing twelve-month figure through Mar 2026 stood at $27.0 million (up 0.87% YoY), and the FY2025 full-year result was $26.9 million, down 1.8% from the prior year.
• Invested Capital for Q1 2026 stood at $27.0 million, roughly flat from $26.9 million in the prior quarter.
• The five-year high for Invested Capital was $64.7 million in Q2 2022, with the low at $26.7 million in Q1 2025.
• Historically, Invested Capital has averaged $33.8 million across 5 years, with a median of $28.1 million in 2023.
• The largest YoY upside for Invested Capital was 265.62% in 2022 against a maximum downside of 64.31% in 2022.
• TherapeuticsMD's Invested Capital stood at $35.1 million in 2022, then retreated by 16.66% to $29.3 million in 2023, then retreated by 6.55% to $27.4 million in 2024, then decreased by 1.8% to $26.9 million in 2025, then gained by 0.36% to $27.0 million in 2026.
• The last three Invested Capital figures came in at $27.0 million (Q1 2026), $26.9 million (Q4 2025), and $27.4 million (Q3 2025), per Business Quant data.